Advertisement

RXi Pharmaceuticals Corp. of Worcester is preparing to bring its first RNAi product into development, with the filing of an investigational new drug (IND) application for its therapeutic candidate in reducing surgical scarring.

RXI-109, its self-delivering RNAi compound, is described by RXi as helping to reduce dermal scarring because of its ability to silence a gene target known to modulate fibrosis. According to an RXi press release, no drugs have been approved yet for dermal anti-scarring.

SOURCE

Advertisement
Advertisement